X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company intends to use the net proceeds to primarily fund the continued advancement of its SMARCA2 portfolio, including its IV molecule, PRT3789, a potent and highly selective SMARCA2 degrader.
Lead Product(s): PRT3789
Therapeutic Area: Oncology Product Name: PRT3789
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 11, 2023
Details:
Under the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize potentially first-in-class treatments for patients with cancer by combining deep expertise in antibody and small molecule development to create precision ADC therapies for patients.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbCellera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 01, 2023
Details:
The net proceeds of the offering will advance company's current clinical pipeline, including PRT2527, PRT1419, PRT3645 and PRT3789, advance its research and discovery efforts including its efforts for a new SMARCA2 oral molecule.
Lead Product(s): PRT2527
Therapeutic Area: Oncology Product Name: PRT2527
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 18, 2023
Details:
Prelude intends to use the net proceeds to advance its current clinical pipeline, including PRT2527, PRT1419, PRT3645 and PRT3789 and advance its research and discovery efforts including its efforts for a new SMARCA2 oral molecule.
Lead Product(s): PRT2527
Therapeutic Area: Oncology Product Name: PRT2527
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 17, 2023
Details:
Under the agreement, BeiGene will provide zanubrutinib to Prelude and will collaborate for future evaluation of Prelude's investigational CDK9 inhibitor, PRT2527, in combination with it’s BTK inhibitor, zanubrutinib, in hematologic malignancies.
Lead Product(s): PRT2527,Zanubrutinib
Therapeutic Area: Oncology Product Name: PRT2527
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2023
Details:
PRT3789 is a Potent and Selective First-in-Class SMARCA2 Protein Degrader. Preclinical models demonstrated that selective degradation of SMARCA2 with potent and highly selective molecule PRT3789, resulted in significant anti-tumor activity at well tolerated doses.
Lead Product(s): PRT3789
Therapeutic Area: Oncology Product Name: PRT3789
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
PRT3645 is a highly potent, selective and brain penetrant CDK4/6 inhibitor that demonstrated greater than 10x brain penetration compared to approved CDK4/6 agents in preclinical models. Prelude intends to develop PRT3645 in the underserved cancers.
Lead Product(s): PRT3645
Therapeutic Area: Oncology Product Name: PRT3645
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
First patient has been dosed in its first-in-human Phase 1 open-label, multicenter, dose-escalation study of PRT1419 in patients with relapsed/refractory hematologic malignancies.
Lead Product(s): PRT1419
Therapeutic Area: Oncology Product Name: PRT1419
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
The company's first clinical candidate, PRT543, is currently in a Phase 1 trial in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies.
Lead Product(s): PRT543
Therapeutic Area: Oncology Product Name: PRT543
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
